These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 18632681)

  • 1. Judge tries to broker treatment deal for patients with macular degeneration in funding row.
    Dyer C
    BMJ; 2008 Jul; 337():a864. PubMed ID: 18632681
    [No Abstract]   [Full Text] [Related]  

  • 2. Should Avastin be used to treat age-related macular degeneration in the NHS?--Yes.
    Raftery J; Dent L
    Eye (Lond); 2009 Jun; 23(6):1247-9. PubMed ID: 19407834
    [No Abstract]   [Full Text] [Related]  

  • 3. The growing importance of pharmacoeconomics: the case of age-related macular degeneration.
    Smith AF
    Br J Ophthalmol; 2010 Sep; 94(9):1116-7. PubMed ID: 20576774
    [No Abstract]   [Full Text] [Related]  

  • 4. [Reimbursement of medical expenses of the exsudative age-related macular degeneration treatment from the public health insurance].
    Pitrová S; Ernest J
    Cesk Slov Oftalmol; 2010 Jul; 66(3):133. PubMed ID: 21137475
    [No Abstract]   [Full Text] [Related]  

  • 5. Doctors warn against using Avastin for macular degeneration.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2483. PubMed ID: 20453011
    [No Abstract]   [Full Text] [Related]  

  • 6. Sight drug deal ends High Court challenge.
    Dyer C
    BMJ; 2008 Jul; 337():a1039. PubMed ID: 18658188
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ranibizumab--effective, but expensive in macular degeneration].
    Frennesson C
    Lakartidningen; 2008 Aug 6-19; 105(32-33):2161. PubMed ID: 18780688
    [No Abstract]   [Full Text] [Related]  

  • 8. Battle over eye medicine gives drugmaker a dose of reality.
    Hayden EC
    Nat Med; 2008 Feb; 14(2):108. PubMed ID: 18256604
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system.
    Neubauer AS; Holz FG; Sauer S; Wasmuth T; Hirneiss C; Kampik A; Schrader W
    Clin Ther; 2010 Jul; 32(7):1343-56. PubMed ID: 20678682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab for Age-related Macular Degeneration.
    Seider MI; Stewart JM
    Ophthalmology; 2011 Aug; 118(8):1693-4; author reply 1694. PubMed ID: 21813100
    [No Abstract]   [Full Text] [Related]  

  • 11. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.
    Gupta OP; Shienbaum G; Patel AH; Fecarotta C; Kaiser RS; Regillo CD
    Ophthalmology; 2010 Nov; 117(11):2134-40. PubMed ID: 20591490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ranibizumab (Lucentis) in the treatment of age-related macular degeneration].
    Studnicka J
    Cesk Slov Oftalmol; 2009 May; 65(3):107-11. PubMed ID: 19642358
    [No Abstract]   [Full Text] [Related]  

  • 13. Value-based medicine.
    Kymes SM; Vollman D; Frick KD
    Ophthalmology; 2008 Nov; 115(11):2099; author reply 2100. PubMed ID: 19068385
    [No Abstract]   [Full Text] [Related]  

  • 14. When is off-label drug use in the patient's best interest?
    Rosenfeld PJ; Goodman KW
    Am J Ophthalmol; 2009 May; 147(5):761-3. PubMed ID: 19376327
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment for wet macular degeneration.
    FDA Consum; 2006; 40(5):6. PubMed ID: 17326303
    [No Abstract]   [Full Text] [Related]  

  • 16. [Promising treatment of neovascular age-related macular degeneration is coming. But to what price?].
    Frennesson C
    Lakartidningen; 2007 Feb 14-20; 104(7):486-7. PubMed ID: 17375677
    [No Abstract]   [Full Text] [Related]  

  • 17. We are part of the problem.
    Bastawrous A; Smith MC
    Br J Ophthalmol; 2008 Jul; 92(7):1010. PubMed ID: 18577659
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes.
    Raja MS; Saldana M; Goldsmith C; Burton BJ
    Br J Ophthalmol; 2010 Nov; 94(11):1543-5. PubMed ID: 20516142
    [No Abstract]   [Full Text] [Related]  

  • 20. Ranibizumab treatment of patients with ocular diseases.
    Dugel PU
    Int Ophthalmol Clin; 2006; 46(4):131-40. PubMed ID: 17060799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.